The Effects of Propolis on Viral Respiratory Diseases.
acute respiratory syndrome coronavirus
clinical trial
in vitro
in vivo
influenza viruses
parainfluenza virus
propolis
respiratory tract diseases
rhinoviruses
Journal
Molecules (Basel, Switzerland)
ISSN: 1420-3049
Titre abrégé: Molecules
Pays: Switzerland
ID NLM: 100964009
Informations de publication
Date de publication:
01 Jan 2023
01 Jan 2023
Historique:
received:
15
10
2022
revised:
18
12
2022
accepted:
24
12
2022
entrez:
8
1
2023
pubmed:
9
1
2023
medline:
11
1
2023
Statut:
epublish
Résumé
Propolis remains an interesting source of natural chemical compounds that show, among others, antibacterial, antifungal, antiviral, antioxidative and anti-inflammatory activities. Due to the growing incidence of respiratory tract infections caused by various pathogenic viruses, complementary methods of prevention and therapy supporting pharmacotherapy are constantly being sought out. The properties of propolis may be important in the prevention and treatment of respiratory tract diseases caused by viruses such as severe acute respiratory syndrome coronavirus 2, influenza viruses, the parainfluenza virus and rhinoviruses. One of the main challenges in recent years has been severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), causing COVID-19. Recently, an increasing number of studies are focusing on the activity of various propolis preparations against SARS-CoV-2 as an adjuvant treatment for this infection. Propolis has shown a few key mechanisms of anti-SARS-CoV-2 action such as: the inhibition of the interaction of the S1 spike protein and ACE-2 protein; decreasing the replication of viruses by diminishing the synthesis of RNA transcripts in cells; decreasing the particles of coronaviruses. The anti-viral effect is observed not only with extracts but also with the single biologically active compounds found in propolis (e.g., apigenin, caffeic acid, chrysin, kaempferol, quercetin). Moreover, propolis is effective in the treatment of hyperglycemia, which increases the risk of SARS-CoV-2 infections. The aim of the literature review was to summarize recent studies from the PubMed database evaluating the antiviral activity of propolis extracts in terms of prevention and the therapy of respiratory tract diseases (in vitro, in vivo, clinical trials). Based upon this review, it was found that in recent years studies have focused mainly on the assessment of the effectiveness of propolis and its chemical components against COVID-19. Propolis exerts wide-spectrum antimicrobial activities; thus, propolis extracts can be an effective option in the prevention and treatment of co-infections associated with diseases of the respiratory tract.
Identifiants
pubmed: 36615554
pii: molecules28010359
doi: 10.3390/molecules28010359
pmc: PMC9824023
pii:
doi:
Substances chimiques
Propolis
9009-62-5
Antiviral Agents
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Références
Biomed Pharmacother. 2020 Nov;131:110622
pubmed: 32890967
Biology (Basel). 2021 Jan 04;10(1):
pubmed: 33406745
Molecules. 2017 Apr 20;22(4):
pubmed: 28425933
Clinicoecon Outcomes Res. 2022 Apr 28;14:293-307
pubmed: 35509962
Arch Pediatr Adolesc Med. 2004 Mar;158(3):217-21
pubmed: 14993078
BMC Complement Med Ther. 2021 Nov 24;21(1):286
pubmed: 34814913
Plants (Basel). 2021 Apr 27;10(5):
pubmed: 33925692
J Ethnopharmacol. 1999 Mar;64(3):235-40
pubmed: 10363838
Environ Sci Pollut Res Int. 2022 Aug;29(39):58628-58647
pubmed: 35794320
Front Cell Infect Microbiol. 2022 Feb 23;12:784130
pubmed: 35281440
Med Res Rev. 2022 Mar;42(2):897-945
pubmed: 34725836
Biomed Pharmacother. 2022 Feb;146:112595
pubmed: 35062065
Antibiotics (Basel). 2021 Aug 26;10(9):
pubmed: 34572627
Molecules. 2022 Feb 28;27(5):
pubmed: 35268700
J Ethnopharmacol. 2008 Oct 30;120(1):108-11
pubmed: 18762235
Microorganisms. 2022 Feb 04;10(2):
pubmed: 35208818
Fundam Clin Pharmacol. 2003 Feb;17(1):93-102
pubmed: 12588635
EClinicalMedicine. 2021 Jun 28;37:100986
pubmed: 34386754
Foods. 2021 Jul 31;10(8):
pubmed: 34441553
Molecules. 2021 Feb 25;26(5):
pubmed: 33669054
J Appl Microbiol. 2007 Nov;103(5):1914-21
pubmed: 17953601
Lancet. 2022 Aug 27;400(10353):693-706
pubmed: 36030813
Phytomedicine. 2021 Jan;80:153368
pubmed: 33091857
Biochem Biophys Rep. 2021 Jul;26:100969
pubmed: 33681482
Antivir Chem Chemother. 2008;19(1):7-13
pubmed: 18610553
J Ethnopharmacol. 2020 Nov 15;262:113159
pubmed: 32736052
Int J Environ Health Res. 2022 Aug 11;:1-13
pubmed: 35951754
Foods. 2021 Jun 11;10(6):
pubmed: 34208334
Complement Ther Med. 2019 Apr;43:81-84
pubmed: 30935560
Biomed Pharmacother. 2021 Jun;138:111526
pubmed: 34311528
Evid Based Complement Alternat Med. 2013;2013:964149
pubmed: 23710243
Dermatol Ther. 2020 Jul;33(4):e13780
pubmed: 32506775
Ann Am Thorac Soc. 2014 Mar;11(3):404-6
pubmed: 24673696
Microb Pathog. 2021 Jul;156:104941
pubmed: 33962007
PLoS One. 2014 Mar 05;9(3):e89668
pubmed: 24598537
J Evid Based Integr Med. 2022 Jan-Dec;27:2515690X211053641
pubmed: 34985368
J Virol. 2004 Oct;78(20):11334-9
pubmed: 15452254
Trials. 2020 Dec 03;21(1):996
pubmed: 33272309
Turk J Pediatr. 2020;62(4):634-640
pubmed: 32779416
Evid Based Complement Alternat Med. 2011;2011:254914
pubmed: 21423687
Clinics (Sao Paulo). 2021 Jan 22;76:e2357
pubmed: 33503192
Front Microbiol. 2021 Jul 20;12:682571
pubmed: 34354682
Phytother Res. 2021 Feb;35(2):743-750
pubmed: 32945590
J Intercult Ethnopharmacol. 2016 Mar 31;5(3):308-11
pubmed: 27366357
J Integr Med. 2022 Mar;20(2):114-125
pubmed: 35144898
Infect Disord Drug Targets. 2022;22(1):e270521193625
pubmed: 34047261
J Pharm Pharmacol. 2021 Mar 6;73(3):281-299
pubmed: 33793885
Curr Pharm Des. 2022;28(29):2415-2425
pubmed: 35899955
Med Drug Discov. 2020 Jun;6:100039
pubmed: 32313880
Curr Pharm Des. 2021;27(38):3996-4007
pubmed: 34225607
Turk J Biol. 2021 Aug 30;45(4):530-548
pubmed: 34803452
Phytochem Rev. 2022;21(6):1887-1911
pubmed: 35645656
J Ethnopharmacol. 2013 Jul 9;148(2):466-73
pubmed: 23643542
Sci Rep. 2020 Oct 19;10(1):17699
pubmed: 33077836
Front Microbiol. 2022 Mar 08;13:799546
pubmed: 35350622
J Nat Prod. 1992 Mar;55(3):294-302
pubmed: 1593279
Int J Pharm. 2021 Jan 5;592:120028
pubmed: 33166584
Phytomed Plus. 2022 Aug;2(3):100280
pubmed: 35463625
Antibiotics (Basel). 2022 Nov 13;11(11):
pubmed: 36421257
Ann Med Surg (Lond). 2022 Aug 18;81:104388
pubmed: 36147103
Saudi J Biol Sci. 2020 Nov;27(11):3079-3086
pubmed: 33100868
Molecules. 2022 Sep 19;27(18):
pubmed: 36144852
Molecules. 2022 Jul 19;27(14):
pubmed: 35889466
Phytother Res. 2021 Jul;35(7):4000-4006
pubmed: 33860587
Planta Med. 2014 Feb;80(2-3):177-82
pubmed: 24458263
Molecules. 2019 May 29;24(11):
pubmed: 31146392
Int J Gen Med. 2016 Nov 11;9:409-414
pubmed: 27956842
Biomedicines. 2019 Sep 21;7(4):
pubmed: 31546676
Evid Based Complement Alternat Med. 2012;2012:946867
pubmed: 21876716